Drug coating with topcoat

Abstract

A coating and method for a coating an implantable device or prostheses are disclosed. The coating includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed herein. The coating further includes a topcoat which covers less than the entire surface of the undercoat and wherein the topcoat comprises a polymeric material substantially free of pores and porosigens. The polymeric material of the topcoat can be a biostable, biocompatible material which provides long term non-thrombogenicity to the device portion during and after release of the biologically active material.

1 - 50 . (canceled)  
   
   
       51 . A medical device comprising: 
 a metallic intravascular stent comprising an open lattice sidewall structure and designed for permanent implantation into a blood vessel of a patient;    a first quantity of a first polymer composition applied to at least a portion of said stent and conforming to said open lattice sidewall structure so as to preserve the open lattice sidewall structure of said stent, wherein said first polymer composition comprises a first biostable polymer and a biologically active material; and    a second quantity of a second polymer composition applied to at least a portion of said first quantity and conforming to said stent so as to preserve the open lattice sidewall structure of said stent, wherein said second polymer composition comprises a second biostable polymer that is different from said first biostable polymer, and wherein said second polymer composition is non-thrombogenic and substantially free of the biologically active material or other elutable material,    wherein when in use, the biologically active material is released from the stent to the blood vessel at a first rate that is different from a second rate, wherein the second rate is the rate of release of the same biologically active material from the stent had the second quantity of the second polymer composition not been applied to the first quantity of the first polymer composition.    
   
   
       52 . The medical device of  claim 51 , wherein the metallic intravascular stent is a stainless steel intravascular stent.  
   
   
       53 . The medical device of  claim 51 , wherein the first quantity of first polymer composition is different from the second quantity of second polymer composition.  
   
   
       54 . The medical device of  claim 51 , wherein the first biostable polymer comprises a hydrophobic elastomeric material, an ethylene vinyl acetate copolymer material, or a mixture thereof.  
   
   
       55 . The medical device of  claim 51 , wherein the biologically active material is an antithrobotic agent, anticoagulant, antibiotic, antiplatelet agent, thrombolytic agent, antiproliferative agent, steroidal antiinflammatory agent, nonsteroidal antiinflammatory agent, agent that inhibits hyperplasia, smooth muscle cell inhibitor, growth factor, growth factor inhibitor, cell adhesion inhibitor, cell adhesion promoter, drug that enhances the formation of healthy neointimal tissue, or a mixture thereof.  
   
   
       56 . The medical device of  claim 51 , wherein the biologically active material is an antibiotic.  
   
   
       57 . The medical device of  claim 51 , wherein the biologically active material inhibits smooth muscle cell.  
   
   
       58 . The medical device of  claim 51 , wherein the biologically active material inhibits restenosis.  
   
   
       59 . The medical device of  claim 51 , wherein the second biostable polymer remains non-thrombogenic during and after release of the biologically active material.  
   
   
       60 . The medical device of  claim 51 , wherein the stent releases the biologically active material over a period of time.  
   
   
       61 . A method of treating restenosis comprising implanting the medical device of  claim 51  into the blood vessel of the patient.  
   
   
       62 . A medical device comprising: 
 a metallic intravascular stent comprising an open lattice sidewall structure and designed for permanent implantation into a blood vessel of a patient;    a first quantity of a first polymer composition applied to at least a portion of said stent and conforming to said open lattice sidewall structure so as to preserve the open lattice sidewall structure of said stent, wherein said first polymer composition comprises an ethylene vinyl acetate copolymer material and an antibiotic; and    a second quantity of a second polymer composition applied to at least a portion of said first quantity and conforming to said stent so as to preserve the open lattice sidewall structure of said stent, wherein said second polymer composition comprises a second biostable polymer that is different from the ethylene vinyl acetate copolymer material of said first polymer composition, and wherein said second polymer composition is non-thrombogenic and substantially free of the antibiotic of the first polymer composition or other elutable material,    wherein when in use, the antibiotic is released from the stent to the blood vessel at a first rate that is different from a second rate, wherein the second rate is the rate of release of the same antibiotic from the stent had the second quantity of the second polymer composition not been applied to the first quantity of the first polymer composition.    
   
   
       63 . The medical device of  claim 62 , wherein the metallic intravascular stent is a stainless steel intravascular stent.  
   
   
       64 . The medical device of  claim 62 , wherein the first quantity of first polymer composition is different from the second quantity of second polymer composition.  
   
   
       65 . The medical device of  claim 62 , wherein the antibiotic inhibits smooth muscle cell.  
   
   
       66 . The medical device of  claim 62 , wherein the antibiotic inhibits restenosis.  
   
   
       67 . The medical device of  claim 62 , wherein the second biostable polymer remains non-thrombogenic during and after release of the antibiotic.  
   
   
       68 . The medical device of  claim 62 , wherein the stent releases the antibiotic over a period of time.  
   
   
       69 . A method of treating restenosis comprising implanting the medical device of  claim 62  into the blood vessel of the patient.